Review

Bench-to-bedside review: Candida infections in the intensive care unit

Marie Méan, Oscar Marchetti and Thierry Calandra

Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

Abstract

Invasive mycoses are life-threatening opportunistic infections and have emerged as a major cause of morbidity and mortality in critically ill patients. This review focuses on recent advances in our understanding of the epidemiology, diagnosis and management of invasive candidiasis, which is the predominant fungal infection in the intensive care unit setting. Candida spp. are the fourth most common cause of bloodstream infections in the USA, but they are a much less common cause of bloodstream infections in Europe. About one-third of episodes of candidaemia occur in the intensive care unit. Until recently, Candida albicans was by far the predominant species, causing up to two-thirds of all cases of invasive candidiasis. However, a shift toward non-albicans Candida spp., such as C. glabrata and C. krusei, with reduced susceptibility to commonly used antifungal agents, was recently observed. Unfortunately, risk factors and clinical manifestations of candidiasis are not specific, and conventional culture methods such as blood culture systems lack sensitivity. Recent studies have shown that detection of circulating β-glucan, mannan and antimannan antibodies may contribute to diagnosis of invasive candidiasis. Early initiation of appropriate antifungal therapy is essential for reducing the morbidity and mortality of invasive fungal infections. For decades, amphotericin B deoxycholate has been the standard therapy, but it is often poorly tolerated and associated with infusion-related acute reactions and nephrotoxicity. Azoles such as fluconazole and itraconazole provided the first treatment alternatives to amphotericin B for candidiasis. In recent years, several new antifungal agents have become available, offering additional therapeutic options for the management of Candida infections. These include lipid formulations of amphotericin B, new azoles (voriconazole and posaconazole) and echinocandins (caspofungin, micafungin and anidulafungin).

Introduction

Fungi have emerged worldwide as an increasingly frequent cause of opportunistic infections. A survey of the epidemiology of sepsis conducted in the USA [1] revealed that the incidence of fungal sepsis increased threefold between 1979 and 2000. In contrast, numerous studies have revealed either no increase or sometimes even a decrease in the incidence of Candida sepsis [2-4]. Candida and Aspergillus spp. are the most frequent causes of invasive fungal infections and are associated with high morbidity and mortality [3,5,6]. The incidence of invasive candidiasis is sevenfold to 15-fold higher than that of invasive aspergillosis [3]. Originally described in immunocompromised hosts, primarily cancer patients, opportunistic fungal pathogens have now been recognized as a frequent cause of infection in surgical and critically ill patients.

The epidemiology of invasive mold infections is changing. Invasive aspergillosis is now also occurring in intensive care unit (ICU) patients, including mechanically ventilated patients and patients with chronic lung diseases treated with corticosteroids [7]. Moreover, the number of strains of non-fumigatus Aspergillus spp. is on the rise and multi-resistant non-Aspergillus mould infections are emerging. Although these are undoubtedly important epidemiological changes, this review article focuses on recent advances in our understanding of the epidemiology, diagnosis and treatment of invasive candidiasis, which is the predominant fungal infection occurring in critically ill patients.

Epidemiology

Candida is now the fourth leading micro-organism responsible for bloodstream infections in the USA, outnumbering all Gram-negative bacilli [8-10]. Data from 790 ICUs reporting to the US National Nosocomial Infection Surveillance system between 1990 and 1999 [8,11] showed that Candida spp. were responsible for 5% to 10% of all bloodstream infections.

Studies of Candida infections in Europe have revealed significant differences from recent trends observed in the USA. In Europe, Candida is usually the sixth to the 10th cause of
nosocomial bloodstream infections [4,12-14]. In a survey conducted by the Fungal Infection Network of Switzerland between 1991 and 2000 [4], ICUs and surgical wards accounted for about two-thirds of all episodes of candidaemia. The incidence of candidaemia (on average 0.5 episodes/10,000 patient-days per year) was stable over this 10-year period and was five to 10 times higher in ICUs than in other wards.

During recent decades, several countries around the world have witnessed a change in the epidemiology of Candida infections, characterized by a progressive shift from a predominance of Candida albicans toward a predominance of non-albicans Candida spp. (including C. glabrata and C. krusei) [15]. C. glabrata has progressively increased and now accounts for 15% to 20% of infections in most countries [16,17]. There is growing evidence suggesting a role in this epidemiological shift for increasing use of azole agents. Reduced susceptibility to commonly used antifungal agents has also been observed in some North American and European centres [18].

In ICU patients, the most common types of Candida infections are bloodstream infections, catheter-related infections, intra-abdominal infections and urinary tract infections [19-23]. Invasive candidiasis is recognized as a leading cause of morbidity and mortality in both immunocompetent and immunocompromised critically ill patients, with reported crude and attributable mortality rates of more than 40% to 60% and 20% to 40%, respectively [13,23-29]. Of note, however, is that in the most recent clinical trials of new antifungal agents [30-35] the overall short-term (end of therapy) and long-term mortality (end of follow up) associated with candidaemia were found to be in the range of 15% to 20% and 30% to 40%, respectively (Figure 1). Candidaemia is also associated with prolonged duration of mechanical ventilation and hospital stay, and increased health care costs [28,36-38].

**Risk factors**

Two main factors predispose to infections with Candida spp.: colonization of skin and mucous membranes with Candida and alteration of natural host barriers (wounds, surgery, and insertion of indwelling intravascular and urinary catheters). The gastrointestinal tract, the skin and the urogenital tract are the main portals of entry for Candida infections. Colonization by Candida spp. has clearly been established as a major risk factor for invasive candidiasis [39]. Together with colonization with Candida induced by profound alteration of the endogenous flora resulting from prolonged broad-spectrum antibiotic therapy and loss of integrity of skin and mucosal barriers, surgery (especially of the abdominal compartment), total parenteral nutrition, acute renal failure, haemodialysis and treatment with immunosuppressive agents are major risk factors for invasive infections with Candida spp. [23,25,40]. Debilitating underlying diseases, critically ill status (as reflected by high Acute Physiology and Chronic Health Evaluation [APACHE] II score), antacids and mechanical ventilation have also frequently been associated with invasive candidiasis. Length of stay in the ICU is also associated with increased risk for Candida infections, which rises rapidly after 7 to 10 days [23,29,41,43].

Prediction rules and scores for identification of non-neutropenic critically ill patients at risk for invasive candidiasis have been reported [39,44-48]. Growth of Candida in semi-quantitative cultures (plating of specimens using the clock-streak technique and a calibrated loop) from multiple body sites has been used to predict the risk for invasive candidiasis [39]. The colonization index, calculated by dividing the number of colonized sites by the number of cultured sites, was found to be significantly higher in patients who developed invasive candidiasis than in control individuals (0.70 ± 0.17 versus 0.47 ± 0.17; P<0.01) [39]. More recently, based on a prospective, cohort, observational, multicentre study that included 73 medical-surgical ICUs in Spain [48], a ‘Candida score’ was developed with the aim being to initiate antifungal therapy early. An adjusted logit model indicated that surgery on ICU admission, total parenteral nutrition, colonization at multiple sites with Candida and severe sepsis were associated with an increased risk for proven Candida infection. Patients with a Candida score, calculated using these variables, of 2.5 or more were 7.5 times more likely to have Candida infections than patients with a score of less than 2.5.

Most recently, an analysis of risk factors in 2,890 patients who stayed in the ICU for more than 4 days led to the development and validation of a clinical prediction rule for the early diagnosis of invasive candidiasis in the ICU [47]. The best prediction rule used a combination of the following factors: any systemic antibiotic or presence of central venous catheter and at least two other risk factors, including total parenteral nutrition, major surgery, pancreatitis, any use of steroids and use of immunosuppressive agents. This prediction rule exhibited a sensitivity of 34%, a specificity of 90%, a positive predictive value of 10% and a negative predictive value of 97%. This clinical rule may therefore help clinicians to rule out invasive candididiasis. However, data on the use of these risk assessment scores for guiding patient management are not yet available and their clinical utility remains to be established in prospective clinical studies.

**Diagnosis**

Given that rapid initiation of appropriate antifungal therapy is crucial for reducing mortality [13,49], prompt diagnosis of infection is of the utmost importance. Unfortunately, diagnosing invasive fungal infections remains difficult and is often delayed. Indeed, blood cultures lack sensitivity (reported to be <50%) [50] and usually become positive late [51]. Invasive tissue sampling is often problematic in critically ill ICU patients. Radiological signs appear often late in the
course of infection. Moreover, the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria for diagnosis of invasive mycoses [52], which are based on clinical, microbiological and radiological criteria, were developed in immunocompromised patients and may not apply to ICU patients. The need for sensitive and specific diagnostic tools has led investigators to look for non-culture-based methods aimed at detecting circulating fungal metabolites, antigens, antibodies and fungal DNA.

Serological tests consist of detection of components of the fungal cell wall, such as mannann, galactomannan and β-(1,3)-D-glucan, or antibodies directed against these antigens (anti-mannann) in blood or other body fluids. These tests have been shown to perform well in clinical studies. For example, three studies were conducted including 5% to 30% of critically ill patients [53-55]. Measurements of mannann and/or anti-mannann led to earlier diagnosis of Candida infection when compared with blood cultures [53,54]. Sensitivity and specificity (respectively) were 40% and 98% for mannann and 53% and 94% for anti-mannann antibodies, and 80% to 90% when combining the two tests [55]. Assays for detection of β-(1,3)-D-glucan are used widely in Japan, and one of these assays (Fungitell; ACC, Falmouth, MA, USA) was recently approved by the US Food and Drug Administration. Studies conducted with β-(1,3)-D-glucan assays have yielded sensitivities ranging from 69% to 97%, specificities ranging from 87% to 100%, and positive and negative predictive values ranging from 59% to 96% and 75% to 97%, respectively [56-59]. Given these excellent negative predictive values β-(1,3)-D-glucan tests can help to rule out invasive candidiasis. Unfortunately, little information has been published thus far on use of β-(1,3)-D-glucan tests in the ICU setting.

Molecular diagnostic tests for detection of Candida DNA in either blood or tissues have been described [60,61]. Albeit promising, relatively few data have been published on the performance of the detection of fungal DNA in high-risk critically ill patients. In addition, these tests are not yet commercially available.

Noninvasive diagnostic tools look promising for early diagnosis of invasive candidiasis. Clinical studies should now be conducted to evaluate their utility for guiding therapeutic decisions (see Pre-emptive therapy, below).

**Antifungal therapy**

**Prophylaxis**

Few prophylactic studies have been performed in ICU patients [43,62-67]. Earlier studies conducted by Savino and coworkers [64] and Slotman and Burchard [63] compared the efficacy of prophylactic administration of oral clotrimazole, ketoconazole, or nystatin with that of placebo in patients selected based either on expected length of stay in the ICU or on baseline risk factors. The results of these underpowered studies revealed either no effect or only a modest impact of prophylaxis on occurrence of Candida infections [68].

In contrast, several more recent studies [43,62,65] indicated that high-risk critically ill patients may benefit from antifungal prophylaxis. Fluconazole prophylaxis was found to prevent intra-abdominal candidiasis in high-risk surgical patients with recurrent gastrointestinal perforations or anastomotic leaks [65]. The risk for intra-abdominal candidiasis was reduced eightfold in patients receiving fluconazole (400 mg/day). One fluconazole-treated patient (4%) developed Candida perito-
nitis as compared with seven placebo-treated patients (35%; \( P = 0.02 \)). The number of patients needed to prevent one episode of intra-abdominal candidiasis was 3, indicating that prophylaxis had considerable impact. Four (20\%) patients died from fungal infections in the placebo group, but none did so in the fluconazole group \( (P = 0.04) \). In a randomized, double-blind, placebo-controlled trial conducted in medical and surgical ICU patients ventilated for at least 48 hours and expected to stay in the ICU for another 72 hours \([62]\), fluconazole prophylaxis \((100 \text{ mg/day})\) exerted a modest protective effect against Candida colonization. Although it did not prevent the development of severe Candida infections, which was the primary study end-point, fluconazole prophylaxis markedly reduced the number of episodes of candidaemia. In the third study, that conducted by Pelz and coworkers \([43]\) in 260 surgical patients expected to stay in the ICU for more than 3 days, 11 (9\%) fungal infections occurred in the fluconazole group as compared with 20 (16\%) in the placebo group \( (P < 0.05) \). Mortality was similar between the two treatment groups.

Overall, these three classic studies strongly suggest that azole prophylaxis has the capacity to reduce the incidence of invasive candidiasis in surgical and ICU patients. However, an important issue remains how to identify those patients who are likely to benefit from prophylaxis without unnecessarily exposing patients who are at either low or no risk to antifungal agents. Indeed, according to a Cochrane review on antifungal agents for the prevention of fungal infections in non-neutropenic critically ill patients \([69]\), the number of patients who should be treated with fluconazole to prevent one Candida infection is 94. This estimate, based on an incidence of fungal infection of 2\%, ranged from 9 in high-risk patients to 188 in low-risk patients. Whether antifungal prophylaxis may have an impact on mortality remains a matter of debate. Although no individual study demonstrates an impact of azole prophylaxis on mortality, the recent Cochrane meta-analysis \([69]\) indicated that prophylaxis did reduce the overall mortality in non-neutropenic critically ill patients. In the 2004 guidelines of the Infectious Diseases Society of America on treatment of candidiasis \([19]\), routine use of antifungal prophylaxis in the general ICU setting was discouraged. However, it was suggested that fluconazole prophylaxis should be considered in carefully selected patients (a recommendation classified as A1, based on the strength of the evidence). These guidelines are being revised and an updated version should be available in 2008.

**Pre-emptive therapy**

There is an extreme paucity of studies on pre-emptive antifungal therapy. In a study conducted between 1998 and 2002 in a surgical ICU in France \([70]\), administration of targeted pre-emptive intravenous fluconazole therapy (fluconazole: 800 mg loading dose and then 400 mg/day for 2 weeks) based on colonization indexes was shown to prevent development of proven candidiasis in ICU patients, when compared with an historical control group of patients. A study conducted in Japan examined the effects of early initiation of pre-emptive therapy with an azole (fluconazole or miconazole in 78\% and 2\% of patients, respectively) or an echinocandin (micafungin in 20\%), which was initiated based on a combination of Candida colonization at multiple sites and a positive \( (1,3)\)-

---

**Treatment of documented Candida infections**

**Polyenes**

For decades amphotericin B deoxycholate has been the standard therapy for invasive fungal infections. Unfortunately, amphotericin B deoxycholate is often poorly tolerated and associated with acute infusion-related reactions and nephrotoxicity. During the late 1970s and 1980s, the development of azoles (miconazole, ketoconazole, fluconazole and itraconazole) provided alternative therapeutic options to amphotericin B for the treatment of candidiasis. In recent years, several new antifungal agents have become available, further enlarging the antifungal armamentarium (Table 1) \([30-35]\). These include lipid formulations (colloidal dispersion, lipid complex and liposomal) of amphotericin B, new azoles (voriconazole and posaconazole) and echinocandins (caspofungin, micafungin and anidulafungin). Lipid formulations of amphotericin B (colloidal dispersion, lipid complex and liposomal) are better tolerated than amphotericin B deoxycholate and have been used mainly in patients who are intolerant to conventional amphotericin B or are unlikely to tolerate it because of altered renal function. Few studies have compared the efficacy of amphotericin B deoxycholate with that of lipid formulations for the treatment of patients with invasive candidiasis \([72,73]\). Small noncomparative studies \([72,73]\) suggested that lipid formulations of amphotericin B are as efficacious as conventional amphotericin B. High costs, a relative paucity of clinical data and existence of alternative antifungal therapies (azoles and echinocandins) explain why lipid formulations have generally been used as second-line therapy in patients with refractory invasive candidiasis.

**Triazoles**

In a multicentre study in non-neutropenic patients with candidaemia, fluconazole \((400 \text{ mg/day})\) was found to be as efficacious as and better tolerated than amphotericin B deoxycholate \((0.5 \text{ to } 0.6 \text{ mg/kg per day})\) \([31]\). Fluconazole remains one of the most commonly used antifungal agents for the treatment of Candida infections. However, innate \((C. krusei)\) or emerging (especially \(C. glabrata\) and \(C. guilliermondii\)) resistance to azoles among non-

---
### Table 1
Randomized multicentre clinical trials of antifungal therapy in patients with candidaemia or invasive candidiasis

| Study                  | Amphotericin B | Liposomal amphotericin B | Anidulafungin | Fluconazole | Voriconazole |
|------------------------|----------------|--------------------------|---------------|-------------|-------------|
| Pappas et al. [30]     | Mica-fungin    | Mica-fungin              | Mica-fungin   | Mica-fungin | Mica-fungin |
| Mora-Duarte et al. [32]| Mica-fungin    | Mica-fungin              | Mica-fungin   | Mica-fungin | Mica-fungin |
| Kuse et al. [34]       | Mica-fungin    | Mica-fungin              | Mica-fungin   | Mica-fungin | Mica-fungin |
| Reboi et al. [35]      | Mica-fungin    | Mica-fungin              | Mica-fungin   | Mica-fungin | Mica-fungin |
| Kullberg et al. [33]   | Mica-fungin    | Mica-fungin              | Mica-fungin   | Mica-fungin | Mica-fungin |
| Rex et al. [31]        | Mica-fungin    | Mica-fungin              | Mica-fungin   | Mica-fungin | Mica-fungin |

#### Daily dose

| Study                  | Daily dose | Mean APACHE II score | Neutrophil count <500/mm³ | Site of infection | Days of therapy | Success of therapy | Drug-related toxicity |
|------------------------|------------|----------------------|-----------------------------|-------------------|-----------------|--------------------|-----------------------|
| Pappas et al. [30]     | 100 mg     | 14.9                 | 11.5%                       | Blood only        | 14 (median)     | At end of iv therapy | Adverse events        |
| Mora-Duarte et al. [32]| 150 mg     | 14.7                 | 8.5%                        | Blood and other site | 14 (median)     | C. glabrata infection | Therapy discontinuation |
| Kuse et al. [34]       | 70 mg      | 14.8                 | 5.9%                        | Other site only   | 14 (median)     | Neutropenia         |                      |
| Reboi et al. [35]      | 70 mg      | 14.8                 | 12.8%                       |                   | 14 (median)     |                      |                      |
| Kullberg et al. [33]   | 100 mg     | 15.6                 | 10.5%                       |                   | 15 (median)     |                      |                      |
| Rex et al. [31]        | 200 mg     | 15.0                 | 13%                         |                   | 15 (median)     |                      |                      |

#### Number of patients

| Study                  | Number of patients | Neutrophil count <500/mm³ | Site of infection | Days of therapy | Success of therapy | Drug-related toxicity |
|------------------------|--------------------|-----------------------------|-------------------|-----------------|--------------------|-----------------------|
| Pappas et al. [30]     | 191                | 11.5%                       | Blood only        | 14 (median)     | At end of iv therapy | Adverse events        |
| Mora-Duarte et al. [32]| 199                | 8.5%                        | Blood and other site | 14 (median)     | C. glabrata infection | Therapy discontinuation |
| Kuse et al. [34]       | 188                | 5.9%                        | Other site only   | 14 (median)     | Neutropenia         |                      |
| Reboi et al. [35]      | 114                | 12.8%                       |                   | 14 (median)     |                      |                      |
| Kullberg et al. [33]   | 125                | 10%                         |                   | 15 (median)     |                      |                      |
| Rex et al. [31]        | 264                | 2%                          |                   | 15 (median)     |                      |                      |

#### Candida spp.

| Study                  | C. albicans | Non-albicans | C. glabrata | C. krusei | Site of infection | Days of therapy | Success of therapy | Drug-related toxicity |
|------------------------|-------------|--------------|-------------|-----------|-------------------|-----------------|--------------------|-----------------------|
| Pappas et al. [30]     | 48.2%       | 54.5%        | 14.7%       | 4.2%      | Blood only        | 14 (median)     | At end of iv therapy | Adverse events        |
| Mora-Duarte et al. [32]| 51.3%       | 54.5%        | 17.1%       | 4.0%      | Blood and other site | 14 (median)     | C. glabrata infection | Therapy discontinuation |
| Kuse et al. [34]       | 44.1%       | 60.6%        | 17.8%       | 2.1%      | Other site only   | 14 (median)     | Neutropenia         |                      |
| Reboi et al. [35]      | 54.1%       | 45.9%        | 12.8%       | 4%        |                   | 14 (median)     |                      |                      |
| Kullberg et al. [33]   | 42%         | 62%          | 11%         | 3%        |                   | 15 (median)     |                      |                      |
| Rex et al. [31]        | 44%         | 59%          | 10%         | 3%        |                   | 15 (median)     |                      |                      |

#### Drug-related toxicity

| Study                  | Adverse events | Therapy discontinuation | Drug-related toxicity |
|------------------------|----------------|-------------------------|-----------------------|
| Pappas et al. [30]     | 22%            | 2.5%                    | Adverse events        |
| Mora-Duarte et al. [32]| 22.8%          | 3.0%                    | Therapy discontinuation |
| Kuse et al. [34]       | 23.8%          | 3.6%                    |                      |
| Reboi et al. [35]      | 75.2%          | 4.9%                    |                      |
| Kullberg et al. [33]   | 50.9%          | 9.0%                    |                      |
| Rex et al. [31]        | 24.4%          | 6%                      |                      |

#### Notes

- Switch to oral fluconazole (400 mg) possible after 10 days of intravenous therapy.
- Switch to oral fluconazole (400 mg) possible after 7 days of intravenous therapy.
- Modified intention-to-treat analyses, if not specified otherwise.
- At end of study drug administration, if not specified otherwise.
- Per protocol analyses.
- Response at 12-week follow-up visit.
- Intention-to-treat analyses, if not specified otherwise.
- Clinical event and/or laboratory abnormality. Modified intention-to-treat analyses. APACHE, Acute Physiology and Chronic Health Evaluation; iv, intravenous; NR, not reported.
1,200 mg) of fluconazole for treatment of less susceptible *Candida* strains are lacking.

Voriconazole, a second-generation triazole that is active against all *Candida* spp., is a new option for intravenous and oral therapy of *Candida* infections [74]. In a randomized, open-label, comparative multicentre, noninferiority trial conducted in patients with invasive *Candida* infections [33], voriconazole (6 mg/kg per day after a 12 mg/kg loading dose on day 1) was shown to be at least as effective as and safer than amphotericin B deoxycholate (0.7 to 1 mg/kg per day) followed by intravenous or oral fluconazole (400 mg/day). Transient, fully reversible visual adverse events and abnormalities of liver function tests are observed in 20% to 40% and 5% to 15% of patients treated with voriconazole, respectively. Efficacy of and/or tolerance to voriconazole may be affected by great variability in blood levels caused by nonlinear pharmacokinetics, polymorphism of cytochrome CYP2C19, drug-drug interactions and hepatic dysfunction [75-77]. Monitoring of circulating drug concentrations to target trough blood values between 1-2 and 6 mg/l would appear prudent, especially during the acute phase of life-threatening infections [78,79].

Itraconazole (an azole that may be administered by oral and intravenous routes) and posaconazole (a new oral azole with a broad spectrum of antifungal activity against *Candida* spp., *Aspergillus* spp. and other emerging molds, including *Fusarium* spp. and zygomycetes) have been shown to be efficacious for treatment of oropharyngeal candidiasis [80,81]. However, no comparative clinical trials in patients with candidaemia have been performed with these antifungal agents, and their efficacy in this clinical setting remains to be determined. One concern, however, might be the potential risk for development of cross-resistance, which could limit the utility of new azoles for therapy of infections due to non- *albicans* *Candida* spp.

**Echinocandins**

Echinocandins are a new class of parenteral antifungal agents that inhibit the synthesis of β-(1,3)-D-glucan in the fungal cell wall [82]. These compounds are fungicidal in *vitro* against *C. albicans* and non- *albicans* *Candida* spp. No cross-resistance with azoles has yet been reported. Three agents are available for clinical use [42,83]: caspofungin, micafungin and anidulafungin. The safety profile of echinocandins is excellent, with few reported adverse events (abnormal liver function tests, phlebitis, or histamine-like reactions). Drug-drug interactions with some medications have been observed with caspofungin (for example, with rifampicin, anticonvulsants, tacrolimus, cyclosporin, protease inhibitors and non-nucleoside reverse transcriptase inhibitors).

Caspofungin was the first echinocandin to be licensed for the treatment of invasive mycoses, including candidiasis [82]. In immunocompromised (mainly HIV-positive) patients with oropharyngeal and/or oesophageal candidiasis, caspofungin was found to be as effective as amphotericin B deoxycholate or fluconazole [84-86]. In a multicentre trial conducted inpatients with invasive candidiasis, caspofungin (50 mg/day after a 70 mg loading dose) was at least as efficacious as and less toxic than amphotericin B deoxycholate (0.6 to 1 mg/kg per day) [32]. Recent reports have described the emergence of resistance to caspofungin in patients with oesophagitis, candidaemia and endocarditis [3]. In a multicentre, randomized, double-blind trial, micafungin (100 mg/day) was as effective as and less toxic than liposomal amphotericin B (3 mg/kg per day) for first-line therapy of candidaemia or invasive candidiasis [34]. In a randomized, double-blind study conducted in patients with invasive candidiasis [35], anidulafungin (100 mg/day after a 200 mg loading dose) was observed to be superior to fluconazole (400 mg/day after a 800 mg loading dose), but the study was reported to show noninferiority after removal of the centre that enrolled the largest number of patients. A recent, randomized, double-blind study comparing micafungin (100 or 150 mg/day) and caspofungin (70 mg loading dose and then 50 mg/day) in 595 adult patients with candidaemia or invasive candidiasis [30] reported noninferior efficacy of micafungin compared with that of caspofungin and similar safety profiles for the two compounds.

Thus, recent studies have shown that echinocandins are efficacious and safe, explaining why this new class of antifungal agents has assumed a prominent role in the management of patients with invasive candidiasis.

**Combinations of antifungal agents**

Given the poor prognosis of *Candida* sepsis in critically ill patients, clinicians have shown interest in using combinations of antifungal agents of different classes. Amphotericin B deoxycholate and 5-flucytosine have been shown to be synergistic in *vitro* and in experimental models of candidiasis [87-89]. Combination of fluconazole and amphotericin B has been shown to be antagonistic in experimental models of aspergillosis, but not in models of invasive candidiasis [90,91]. However, there is a dearth of information available from few clinical studies. In a randomized, double-blind study conducted in non-neutropenic patients with candidaemia [92], high-dose fluconazole (800 mg/day intravenously) was compared with a combination of fluconazole (800 mg/day intravenously) and amphotericin B deoxycholate (0.7 mg/kg per day intravenously). At first glance, the efficacy of combination therapy was slightly superior to that of monotherapy (success: 69% versus 56%), especially in patients with an APACHE II score ranging between 10 and 22. However, there were statistically significant differences in baseline covariates between the two groups, such as APACHE II score, which was lower in the combination treatment arm. Until clinical trials are reported that demonstrate efficacy and safety, the indiscriminate use of combination therapy in patients with invasive candidiasis should be discouraged.
Conclusion
Invasive candidiasis is the most frequent invasive mycosis in critically ill patients. Changing epidemiology with increased non-albicans *Candida* spp., nonspecific risk factors and clinical presentation, and late diagnosis with culture-based methods are major challenges in the management of invasive candidiasis. Preventive strategies targeting patients with a high-risk profile, development of new noninvasive diagnostic tools that allow early diagnosis and therapy, and extension of the therapeutic armamentarium with new agents are encouraging recent advances that may allow us to overcome *Candida* infections.

Competing interests
The authors declare that they have no competing interests.

References
1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003, 348:1546-1554.
2. Lagrou K, Verhaegen J, Peetermans WE, De RT, Maertens J, Van WE: *Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species*. *Eur J Clin Microbiol Infect Dis* 2007, 26:541-547.
3. Pfaller MA, Diekema DJ: *Epidemiology of invasive candidiasis: a persistent public health problem*. *Clin Microbiol Rev* 2007, 20:133-163.
4. Marchetti O, Bille J, Fluckiger U, Eggimann P, Pittet D: Epidemiology of *Candida* infections in Swiss tertiary care hospitals: secular trends, 1991-2000. *Clin Infect Dis* 2004, 38:311-320.
5. Patterson TF, Kirkpatrick WR, White M, Hiemstra Y, Nitenberg G, Nystrom PO, Pittet D, et al.: *Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000*. *Clin Infect Dis* 2004, 38:311-320.
6. Patterson TF, Kirkpatrick WR, White M, Hiemstra Y, Nitenberg G, Nystrom PO, Pittet D, et al.: *Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000*. *Clin Infect Dis* 2004, 38:311-320.
7. Lin SJ, Schranz J, Teutsch SM: *Aspergillosis case-fatality rate: systematic review of the literature*. *Clin Infect Dis* 2001, 32:358-366.
8. Bille J, Marchetti C, Fournier PE, et al.: *Aspergillosis case-fatality rate: a systematic review of the literature*. *Clin Infect Dis* 2002, 34:314-319.
9. Richards MJ, Edwards JR, Culver DH, Gaynes RP: *Nosocomial infections in combined medical-surgical intensive care units in the United States*. *Infect Control Hosp Epidemiol* 2000, 21:510-515.
10. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JR, Jarvis W, Dawson J, et al.: *National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units*. *Clin Infect Dis* 1999, 29:253-258.
11. Wisplinghoff H, Seifert H, Wenzel RP: *Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States*. *Clin Infect Dis* 2003, 36:1103-1110.
12. Wisplinghoff H, Bishoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: *Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study*. *Clin Infect Dis* 2004, 38:309-317.

Available online http://ccforum.com/content/12/1/204
30. Pappas PG, Gotzheim CM, Betts RF, Nucci M, Talwar D, De Weale JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, et al.: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.

31. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Schedel WM, Karchmer AW, Dine AP, et al.: A randomized trial comparing fluconazole with amphotericin B for treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331:1325-1330.

32. Mora-Duarte J, Betts R, Rosfell C, Colombo AL, Thompson-Moya L, Stelanti J, Lupinacci R, Sable C, Kartsonis N, Perfect J: Perfect JD, Wenzel RP: Micafungin versus caspofungin for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.

33. Kulberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole in patients with candidemia: a randomised non-inferiority trial. Lancet 2005, 366:1430-1442.

34. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Teshima H, Kohno S, Horiuchi A, Ito A, Teshima H, Kohn S, Horuchi A, Ito A, et al.: Evaluation of plasma (1 -> 3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin Biochem 1995, 33:555-560.

35. Obayashi T, Yoshihara M, Mori T, Goto H, Yasuoka A, Iwasaki H, Teshima H, Kohn S, Horuchi A, Ito A, et al.: Plasma (1 -> 3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345:17-20.

36. Garey KW, Rege M, Pai MP, Minge DO, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:263-271.

37. Reiss E, Morrison CJ: Nonculture methods for diagnosis of disseminated candidiasis. Clin Microbiol Rev 1993, 6:311-323.

38. Morris AJ, Byrne TC, Maddan JF, Reiller LB: Duration of incubation of fungal cultures. J Clin Microbiol 1996, 34:1583-1585.

39. Angulo S, Rex JH, Bennett JE, Bille J, Crook AD, Denning DW, Donnelly JP, Edwards JE, Enaie J, et al.: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:155-164.

40. Yer A, Sendid B, Francois N, Camus D, Poulain D: Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 2001, 20: 864-870.

41. Borello RX, Piotrow JS, Tabouret M, Bonnin A, Cailloit D, Camus D, Poulain D: Combined detection of mannanemia and antifungal antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002, 51:433-442.

42. Sendid B, Tabouret M, Poirier JL, Mathieu D, Fruit J, Poulain D: New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antifungal antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999, 37:105-117.

43. Mori T, Ikemoto H, Matsumura M, Yoshida M, Inada K, Endo S, Ito A, Watanabe S, Yamaguchi H, Mitsuya M, et al.: Evaluation of plasma (1 -> 3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin Biochem 1995, 33:555-560.

44. Sera D, Mattia M, Cefalu G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Poulain D, et al.: Micafungin versus fluconazole for candidaemia in non-neutropenic patients: a randomised double-blind trial. Eur J Clin Microbiol Infect Dis 2004, 23:271-276.

45.Slotman GJ, Burchard KW, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:263-271.

46. Sheena E, Hebart H, Roller G, Loffler J, Rothenhofer I, Muller CA, Bowden RA, van BJ, Engelhard D, Kanz L, et al.: Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997, 35:1383-1380.

47. Garbino J, Lew DP, Romond JA, Hugonnert S, Ackenhahler R, Pitett D: Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002, 28:1708-1717.

48. Slotman G, Burchard KW: Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987, 122: 147-151.

49. Arch E, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L: Routine prophylactic antifungal agents ( clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994, 36:20-25.

50. Eggimann P, Francioli P, De Vriend J, van der Horst CM, Luttinger J, et al.: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999, 27:1066-1072.

51. Lumbere M, Cuervas-Mons V, Jara P, del PA, Tumon VS, Banios C, Moreno E, Noriega AR, Paya CV: Randomized trial of fluconazole versus amphotericin B for intensive care unit patients with peritonitis. Crit Care Med 2001, 29:2011-2017.

52. Kulbeck T, Schaffner F, Kett DH, Saavedra P, Almirante B, Nolla-Salas J, et al.: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
conazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996, 174:583-588.

67. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32:1191-1200.

68. Calandra T, Marchetti O: Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004, Suppl 4:185-192.

69. Playford EG, Webster AC, Sorrell TC, Craig JC: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006, 1:CD004920.

70. Pirotta R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Infect J A: 2006, 42:1179-1186.

71. Tsuruta R, Mizuno H, Kaneko T, Oda Y, Kaneda K, Fujita M, Inoue T, Kasaoka S, Maekawa T: Preemptive therapy in non-neutrolysis patients with Candida infection using the Japanese guidelines. Ann Pharmacother 2007, 41:1137-1143.

72. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA: Voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007, 51:137-143.

73. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.

74. Arathoon EG, Gotuzzo E, Sable CA: Randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Am J Med 2002, 113:294-299.

75. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Berman RS, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophageal candidiasis. Am J Med 2001, 133:1529-1533.

76. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113:294-299.

77. Pascual A, Nieth V, Calandra T, Bolay S, Buclin T, Majcherczyk PA, Sanglard D, Marchetti O: Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007, 51:137-143.

78. Andes D, Greaves W, Isaacs R: Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother 1997, 41:1345-1348.

79. Arathoon EG, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.

80. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, Sable CA: Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother 1997, 41:1345-1348.

81. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.

82. Vazquez JA, Gotuzzo E, Sable CA: Randomized, double-blind study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasises. Antimicrob Agents Chemother 2002, 46:451-457.